Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

115
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within...
115
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

160
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
160
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

251
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and...
251
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

2.0K
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
2.0K
Factors Affecting Drug Distribution: Physiological Barriers01:23

Factors Affecting Drug Distribution: Physiological Barriers

1.0K
Drug distribution in the body is intricately regulated by various physiological barriers that control the passage of substances. These include the capillary endothelial barrier, the blood-brain, blood-cerebrospinal fluid, blood-placental, and blood-testis barriers.
The capillary endothelial barrier allows only smaller molecules below 600 Da (Daltons) to pass through. It also restricts drugs like heparin that are bound to blood components, limiting their movement within the bloodstream.
The...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Imaging the hallmarks of cancer.

Nature reviews. Cancer·2026
Same author

Super-Resolution Ultrasound Based Cell Tracking With Polymeric Nanobubbles.

Advanced materials (Deerfield Beach, Fla.)·2026
Same author

Clinical translation and landscape of stimuli-responsive nanomedicines and microscale therapeutics.

Chemical Society reviews·2026
Same author

Validation of an automated AI-based micro-CT organ segmentation workflow against expert annotations and its impact on fluorescence quantification.

European radiology experimental·2026
Same author

Future Challenges of Molecular Imaging in Oncology.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same author

Molecular Ultrasound Imaging.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026

Related Experiment Video

Updated: May 7, 2026

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
11:56

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection

Published on: October 25, 2013

16.3K

Multidrug resistance: Physiological principles and nanomedical solutions.

Sijumon Kunjachan1, Błażej Rychlik2, Gert Storm3,4

  • 1Department of Experimental Molecular Imaging, Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Pauwelsstrasse 30, 52074 Aachen, Germany.

Advanced Drug Delivery Reviews
|October 15, 2013
PubMed
Summary

Multidrug resistance (MDR) in cancer limits chemotherapy effectiveness due to drug efflux pumps. Nanomedicine offers strategies to overcome MDR by using novel drug delivery systems and combination therapies.

Keywords:
ABC transportersDrug efflux pumpsDrug targetingMDRMRPMultidrug resistanceNanomedicinePgpPluronicssiRNA

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

12.8K
Author Spotlight: Exploring the Antibacterial Effects of Zinc Oxide Nanoparticles in Overcoming Antibiotic Resistance
06:42

Author Spotlight: Exploring the Antibacterial Effects of Zinc Oxide Nanoparticles in Overcoming Antibiotic Resistance

Published on: September 27, 2024

3.0K

Related Experiment Videos

Last Updated: May 7, 2026

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
11:56

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection

Published on: October 25, 2013

16.3K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

12.8K
Author Spotlight: Exploring the Antibacterial Effects of Zinc Oxide Nanoparticles in Overcoming Antibiotic Resistance
06:42

Author Spotlight: Exploring the Antibacterial Effects of Zinc Oxide Nanoparticles in Overcoming Antibiotic Resistance

Published on: September 27, 2024

3.0K

Area of Science:

  • Oncology
  • Nanomedicine
  • Pharmacology

Background:

  • Multidrug resistance (MDR) in cancer cells impedes effective chemotherapy.
  • Overexpression of ATP-binding cassette (ABC) transporters like P-glycoprotein (Pgp/ABCB1) and MRP (ABCC1) drives MDR.
  • Current chemotherapeutic strategies face limitations due to MDR.

Purpose of the Study:

  • To review nanomedical strategies for overcoming MDR in cancer.
  • To discuss the physiological basis of MDR and its molecular mechanisms.
  • To explore the potential of nanomedicine in treating multidrug-resistant malignancies.

Main Methods:

  • Review of existing literature on MDR mechanisms and nanomedicine applications.
  • Analysis of strategies involving carrier materials with anti-MDR properties.
  • Evaluation of nanomedicines for altering cellular drug uptake.
  • Assessment of co-formulation approaches combining drugs with MDR inhibitors.

Main Results:

  • Nanomedicine offers diverse strategies to combat MDR, including intrinsic anti-MDR materials and modified cellular uptake.
  • Co-formulation of chemotherapeutics with MDR inhibitors in nanodelivery systems shows promise.
  • Nanomedical approaches can overcome limitations imposed by drug efflux pumps.

Conclusions:

  • Nanomedicine formulations demonstrate significant potential for improving treatment outcomes in multidrug-resistant cancers.
  • While clinical translation faces challenges, nanomedicine represents a promising frontier in oncology.
  • Further research and development are crucial for widespread clinical application of these nanomedical strategies.